Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
Irene Konstantopoulou, PhD
Advertisement
Articles by Irene Konstantopoulou, PhD
Advertisement
Latest Updated Articles
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETsPublished: July 10th 2024 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: Key Anticipated Updates in Breast and Lung Tumors
2
Ficerafusp Alfa/Pembrolizumab Receives FDA BTD in Front-Line HNSCC
3
Tucatinib Regimen Improves PFS in HER2+ Metastatic Breast Cancer
4
Safety Strategies for GPRC5D-Directed and T-Cell Engager Therapies
5
